Standout Papers

Post-translational modification of p53 in tumorigenesis 2004 2026 2011 2018 977
  1. Post-translational modification of p53 in tumorigenesis (2004)
    Ann M. Bode, Zigang Dong Nature reviews. Cancer
  2. AKT as a Therapeutic Target for Cancer (2019)
    Mengqiu Song, Ann M. Bode et al. Cancer Research
  3. Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy (2021)
    Ruijuan Du, Chuntian Huang et al. Molecular Cancer
  4. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery (2024)
    Yamei Hu, Zigang Dong et al. Journal of Experimental & Clinical Cancer Research
  5. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches (2024)
    Fangfang Liu, Kai Li et al. Molecular Cancer
  6. Inflammation in cancer: therapeutic opportunities from new insights (2025)
    Fangfang Liu, Yao Zhu et al. Molecular Cancer

Immediate Impact

18 by Nobel laureates 17 from Science/Nature 57 standout
Sub-graph 1 of 22

Citing Papers

USP8-governed GPX4 homeostasis orchestrates ferroptosis and cancer immunotherapy
2024 Standout
Chalcone: A Privileged Structure in Medicinal Chemistry
2017 Standout
6 intermediate papers

Works of Zigang Dong being referenced

Isoliquiritigenin Induces Apoptosis and Inhibits Xenograft Tumor Growth of Human Lung Cancer Cells by Targeting Both Wild Type and L858R/T790M Mutant EGFR
2014
Molecular targets of phytochemicals for cancer prevention
2011
and 2 more

Author Peers

Author Last Decade Papers Cites
Zigang Dong 16809 5558 4314 572 27.2k
Ann M. Bode 12196 4058 3207 415 20.5k
Thomas W. Kensler 28371 2410 4582 400 41.4k
Young‐Joon Surh 14409 2341 2963 406 27.0k
Nihal Ahmad 8363 2990 2166 234 22.3k
Paul Talalay 28424 3377 2092 253 39.4k
Yung Hyun Choi 12297 2455 2871 910 23.8k
I. Bernard Weinstein 13540 5831 4073 375 21.7k
Gautam Sethi 25491 8505 8942 605 46.2k
Hong Zhang 12121 3580 2677 917 24.2k
Thomas Efferth 16836 6295 3709 944 35.4k

All Works

Loading papers...

Rankless by CCL
2026